Bacterial antigens unleash tumor-targeting immunity
- PMID: 38096784
- PMCID: PMC11075005
- DOI: 10.1016/j.chom.2023.11.001
Bacterial antigens unleash tumor-targeting immunity
Abstract
The composition of the gut microbiome has been shown to influence disease outcome in patients with colorectal cancer (CRC). In a recent Nature Biotechnology article, Wang et al. demonstrate that killing CRC-associated bacteria with a liposomal antibiotic elicits CRC-targeting immune responses of therapeutic relevance as a consequence of epitope mimicry.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options.
Figures
Comment on
-
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses.Nat Biotechnol. 2024 Aug;42(8):1263-1274. doi: 10.1038/s41587-023-01957-8. Epub 2023 Sep 25. Nat Biotechnol. 2024. PMID: 37749267
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
